ArticleFrontiers in cardiovascular medicine2025
Chronic intermittent hypoxia exacerbates isoproterenol-induced cardiac hypertrophy and apoptosis.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obstructive sleep apnea (OSA) is marked by chronic intermittent hypoxia (CIH) and iassociated with multiple cardiovascular complications. Isoproterenol (ISO) is commonly used to induce cardiac hypertrophy. However, the impact of CIH on ISO-induced cardiac hypertrophy and remodeling remains unclear. Methods: Cardiac hypertrophy was induced in mice using ISO, with or without CIH. Echocardiography was performed to assess cardiac functions, while histological analyses were employed to evaluate the physiological modifications in the heart. Western blotting and real-time quantitative PCR were used to evaluate protein and mRNA gene expression levels, respectively. Additionally, immunofluorescence was employed to observe the morphological changes in H9C2 cells. Results: CIH exacerbated ISO-induced cardiac dysfunction and cardiac pathological alterations in mice. The expression of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) was elevated in both mice and H9C2 cells in the CIH + ISO group. Furthermore, CIH exacerbated ISO-induced cell apoptosis. We additionally observed that the PI3K/AKT/mTOR pathway is further activated by the co-induction of CIH and ISO. Conclusions: CIH exhibits a negative effect on ISO-treated mice and cells, leading to an exacerbation of cardiac dysfunction and remodeling. In addition, CIH aggravates ISO-treated cardiomyocyte apoptosis in H9C2 cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.